期刊
JOURNAL OF HEART AND LUNG TRANSPLANTATION
卷 42, 期 11, 页码 1510-1514出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2023.07.008
关键词
HVAD; clinical outcomes; mortality; neurological events; recall; intermacs
Based on the quarterly reports from 2022, there seems to be no increase in mortality, stroke, pump thrombus, or device explant for patients supported by the HVAD system after the market withdrawal and recent device recalls.
In June 2021, HVAD System distribution ceased due to observational data demonstrating increased mortality and neurological events compared to another commercial device, and a device malfunction with delay or failure to restart, especially in certain subpopulations. To assess ongoing risk for patients on support following subsequent device recalls, the manufacturer's Intermacs HVAD System 2022 Quarterly Reports were queried to identify mortality and adverse events trends in a contemporary cohort of 3110 primary HVAD implantations since October 2017, stratified by year-of-implant. Mean duration of support was 21 +/- 16 months, with 33% alive on original device, 25% transplanted, 6% undergoing device exchange, 4% recovered, and 32% expired. Kaplan-Meier and event-per-patient-year estimates for survival, freedom from device explant, stroke, and pump thrombus were similar across year-of-implant. Following market withdrawal and recent device recalls, there appears to be no increase in mortality, stroke, pump thrombus, or explant for HVAD-supported patients. Quarterly report monitoring is ongoing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据